Vertex Pharmaceuticals (VRTX)
$410.24
7.74 (1.92%)
VRTX Stock Quote Delayed 30 Minutes
VRTX Stock Earnings: Vertex Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
VRTX stock results show that Vertex Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
106.43B
PE Ratio
29.53
EPS
13.89
Volume (Avg. Vol.)
1.61M
Day's Range
$394.03 - $415.67
52-Week Range
$320.01 - $448.40
Dividend & Yield
N/A (N/A)
VRTX Stock Predictions, Articles, and Vertex Pharmaceuticals News
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
3 Underappreciated Healthcare Stocks to Buy Now: April 2024
Novo Nordisk (NVO), United Therapeutics (UTHR) and Vertex Pharmaceuticals (VRTX) are three underappreciated healthcare stocks to buy in April.
3 Biopharma Stocks Predicted to Soar in Q2 2024
These biopharma stocks can produce massive returns for Q2 based on new product releases and international treatment approvals.
